USP Chapter Emphasizes Problems With Revision Process - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP Chapter Emphasizes Problems With Revision Process
Inaccuracies in Chapter 91072: of the current USP 29 reveal problems in USP's revision and proofreading process.


Pharmaceutical Technology




The United States Pharmacopia has been recognized for years as an authoritative compendium on drug standards. In recent years, it has paid increasing attention to "microbial purity," i.e., freedom from and control of objectionable bacteria and fungi and included writings on the theory and practice of antimicrobial agents. A reading of Chapter ‹1072› in current USP 29 (Antiseptics and Disinfectants), however, reveals inaccuracies in organic chemistry, proper selection of agents, and ingredient concentrations. Although these errors or inaccuracies do not affect drug purity, they are evidence of a revision process that fails to circulate early drafts to the right people.

Item No. 1: The remarks following Table 3 in Chapter ‹1072› discuss the ionization of weak acids such as phenol and acetic acid, both rarely used in the pharmaceutical plant as microbicides. It is correctly stated that phenol is more active in killing microorganisms below pH 7.0 because it is mostly un-ionized. The same common ion effect would be obtained for acetic acid as well, but the author reverses the equation and states that "acetic acid will be more effective at a pH below 4.0 where it is ionized" (1). The equation is






The pKa of acetic acid is 4.55. By the rule of 2-above-2-below, at pH 6.55 the acid is highly ionized and at pH 2.55 it is practically all un-ionized. At pH 4.0, as cited by the author, it cannot be said to be "ionized;" as a matter of fact, about 90% is just the opposite. Thus, fungi and a few aciduric bacteria will be killed rapidly because the molecule exists mainly as HOAc un-ionized. This pH-dependant lethality is, we believe, what the author tried to convey. But if what is said is not clear, it should not be said.

Item No. 2: Table 2 misspells glutaraldehyde, and Table 4 mistakenly lists glutaraldehyde as an oxidizing agent. Glutaraldehyde exerts its effect by covalent bonding to amino groups or other susceptible sites on nucleic acids or polypeptide chains. In chemistry, a nucleophile (literally, "nucleus lover") is a reagent that forms a chemical bond to its reaction partner (the electrophile) by donating both bonding electrons. Its mechanism is the same as formaldehyde but it is less toxic. No manufacturer of this germicide has ever claimed glutaraldehyde to be an oxidizing agent, like chlorine, nor will any textbook of organic chemistry so state. A common definition of an oxidizing agent is a substance that gains electrons in a redox chemical reaction.

In this same table, ethylene oxide is listed as an oxidizing agent. For classification purposes, it should be grouped with formaldehyde and glutaraldehyde. It is an alkylating agent. Alkylating agents increase the size of a molecule, oxidizing agents generally degrade them.

Item No. 3: In Table 2, "General Classification of Antiseptics, Disinfectants, and Sporicidal Agents," benzalkonium chloride is listed at a use concentration of 200 μg/g. This single concentration does not fit any of the standard marketed products now available that might include this agent. For example, it is too low for use as a disinfectant, for first-aid preparation, or for cosmetic use (the usual range is 1000–3000 μg/g for these uses) and it is too high to be used as an ophthalmic preservative, for which the range is 30–100 μg/g.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here